Please login to the form below

Not currently logged in
Email:
Password:

BTK inhibitor

This page shows the latest BTK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi sees double-digit growth driven by ‘megabrand’ Dupixent

Sanofi sees double-digit growth driven by ‘megabrand’ Dupixent

Other drugs that were delayed include tusamitamab in lung cancer and BTK inhibitor rilzabrutinib (which the company acquired from the $3.7bn Principia Biopharma deal).

Latest news

More from news
Approximately 2 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica. ... Its BTK inhibitor zanubrutinib was granted Fast Track designation by the US FDA in

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Deal Watch January 2018

    Collaboration, licence. 380. Jiangsu Hengrui Medicine/TG Therapeutics. BTK inhibitor programme, incl lead candidate TG-1701 (p1) and another BTK inhibitor (pc). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Deal Watch November 2015 Deal Watch November 2015

    Overall 2015 has been a very busy year for Hanmi which in March closed a $690m deal with Lilly for a phase 1 BTK-inhibitor in autoimmune indications and also in ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration, licence. Sotagliflozin, p3 oral

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....